文 献1）Goodwin ML, Drew RH. Antifungal serum concentration monitoring: an update. J Antimicrob Chemother 2008; 61: 17-25.2）Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46: 201-11.3）Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003; 36: 630-7.4）Yamada T, Mino Y, Yagi T, Naito T, Kawakami J. Saturated metabolism of voriconazole N-oxidation resulting in nonlinearity of pharmacokinetics of voriconazole at clinical doses. Biol Pharm Bull 2015; 38: 1496-503.5）Li X, Yu C, Wang T, Chen K, Zhai S, Tang H. Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: a systematic review and meta-analysis. Eur J Clin Pharmacol 2016; 72: 1185-93.6）Yanni SB, Annaert PP, Augustijns P, Bridges A, Gao Y, Benjamin DK, et al. Role of flavin-containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomes. Drug Metab Dispos 2010; 38: 25-31.7）Sachse C, Ruschen S, Dettling M, Schley J, Bauer S, Müller-Oerlinghausen B, et al. Flavin monooxygenase 3 (FMO3) polymorphism in a white population: allele requencies, mutation linkage, and functional effects on clozapine and caffeine metabolism. Clin Pharmacol Ther 1999; 66: 431-8.8）Williams K, Mansh M, Chin-Hong P, Singer J, Arron ST. Voriconazole-associated cutaneous malignancy: a literature review on photocarcinogenesis in organ transplant recipients. Clin Infect Dis 2014; 58: 997-1002.易感染性患者におけるVRCZのNオキシド化代謝経路に着目した薬物動態・薬力学的評価9）Yamada T, Mino Y, Yagi T, Naito T, Kawakami J. Rapid simultaneous determination of voriconazole and its N-oxide in human plasma using an isocratic high-performance liquid chromatography method and its clinical application. Clin Biochem 2012; 45: 134-8.10）Naito T, Yamada T, Mino Y, Kawakami J. Impact of inflammation and concomitant glucocorticoid administration on plasma concentration of triazole antifungals in immunocompromised patients. Clin Chim Acta 2015; 441: 127-32.11）Yeung CK, Adman ET, Rettie AE. Functional characterization of genetic variants of human FMO3 associated with trimethylaminuria. Arch Biochem Biophys 2007; 464: 251-9.12）Hao DC, Sun J, Furnes B, Schlenk D, Hou ZF, Zhang YP, et al. Haplotype frequency distribution and linkage disequilibrium analysis of single nucleotide polymorphisms at the human FMO3 gene locus. Biochem Genet 2006; 44: 391-407.13）Furuta T, Shirai N, Kodaira M, Sugimoto M, Nogaki A, Kuriyama S, et al. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther 2007; 81: 521-8.14）Sugimoto K, Uno T, Yamazaki H, Tateishi T. Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population. Br J Clin Pharmacol 2008; 65: 437-9.15）Li X, Yu C, Wang T, Chen K, Zhai S, Tang H. Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: a systematic review and meta-analysis. Eur J Clin Pharmacol 2016; 72: 1185-93.115
元のページ ../index.html#129